News
Novartis exited novel antibiotics R&D three years ago ... The deal covers global rights to three brands – Zinnat (cefuroxime axetil), Zinacef (cefuroxime) and Fortum (ceftazidime) – which ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback